doctors have made significant progress treating RA. That's mostly due to two types of prescriptions, disease-modifying antirheumatic drugs or DMARDs and biologics. Conventional DMARDs including ...

Using biologic therapy, we can try and tailor the treatment towards getting a particular person's rheumatoid arthritis under better control. There's no one-size-fits-all type of an answer for ...

Original Medicare covers most medically necessary rheumatoid arthritis (RA) treatments, including biologics. Medicare Part D or Part B covers eligible prescription drug expenses. Which one covers ...

Biologic disease-modifying antirheumatic drugs (bDMARDs) do not appear to negatively impact fertility among women with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to study ...

Exploring Regulatory Affairs, the discipline dedicated to ensuring that new drugs and biologics are safe, effective, and ...

The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo-controlled trial (RADIATE) of patients with RA who demonstrated an ...

Medication options are numerous for treating RA. They include over-the-counter (OTC) and prescription anti-inflammatory medications and pain relievers, corticosteroids, non-biologic DMARDs ...

Among US veterans with rheumatoid arthritis, the use of biologic/targeted synthetic DMARDs does not appear to increase the risk of developing multiple myeloma. The use of biologic and targeted ...

The efficacy is said to be equal or slightly better than biological agents ... there has been great advancements in treating rheumatoid arthritis.

A safe and effective oral drug would threaten several multibillion-dollar biologic franchises, not only in rheumatoid arthritis but also in several other autoimmune conditions, including Crohn's ...

Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...

Switching among biologic therapies is common practice in patients with rheumatoid arthritis who have an inadequate response or intolerable adverse events. Evidence from observational studies and ...